134038-88-3

Upstream product

• 2916-68-9 2-(Trimethylsilyl)ethanol 
• 89525-07-5 (+/-)-2-<(benzyloxycarbonyl)amino>-2-(dimethoxyphosphinyl)acetic acid 
• 121-45-9 phosphorous acid trimethyl ester 
• 79002-45-2 N-benzyloxycarbonyl-glycine 
• 257933-01-0 2-(trimethylsilyl)ethyl α-hydroxy-N-(benzyloxycarbonyl)glycinate 
• 100945-15-1 N-(benzyloxycarbonyl)phosphonoglycine trimethyl ester 

Downstream Products

• 142602-59-3 (E)-2-Benzyloxycarbonylamino-3-[4,4'-bis-benzyloxy-3'-(2-tert-butoxycarbonylamino-1-hydroxy-2-methoxycarbonyl-ethyl)-biphenyl-3-yl]-acrylic acid 2-trimethylsilanyl-ethyl ester 
• 142602-59-3 (Z)-2-Benzyloxycarbonylamino-3-[4,4'-bis-benzyloxy-3'-(2-tert-butoxycarbonylamino-1-hydroxy-2-methoxycarbonyl-ethyl)-biphenyl-3-yl]-acrylic acid 2-trimethylsilanyl-ethyl ester 
• 143164-83-4 4,4'-dibenzyloxy-3-<(S)-2-(tert-butoxycarbonylamino)-2-(methoxycarbonyl)-(R)-1-hydroxyethyl>-3'-<(Z)-2-(benzyloxycarbonylamino)-2-(trimethylsilylethoxycarbonyl)vinyl>biphenyl 
• 121141-60-4 (E)-2-Benzyloxycarbonylamino-3-[3'-((S)-2-benzyloxycarbonyl-2-tert-butoxycarbonylamino-ethyl)-4,4'-dimethoxy-biphenyl-3-yl]-acrylic acid 2-trimethylsilanyl-ethyl ester 
• 121125-07-3 (Z)-2-Benzyloxycarbonylamino-3-[3'-((S)-2-benzyloxycarbonyl-2-tert-butoxycarbonylamino-ethyl)-4,4'-dimethoxy-biphenyl-3-yl]-acrylic acid 2-trimethylsilanyl-ethyl ester 
• 247167-35-7 (Z,Z)-4-{5-[2-[(benzyloxycarbonyl)amino]-2-(methoxycarbonyl)ethenyl]-2-methoxyphenoxy}-1-{2-[(tert-butyloxycarbonyl)amino]-2-[[2-(trimethylsilyl)ethoxy]carbonyl]ethenyl}benzene 
• 143164-87-8 (2S,3R)-2-((2S,4R)-5-Benzyloxycarbonylamino-2-tert-butoxycarbonylamino-4-hydroxy-pentanoylamino)-3-{4,4'-bis-benzyloxy-3'-[(S)-2-benzyloxycarbonylamino-2-(2-trimethylsilanyl-ethoxycarbonyl)-ethyl]-biphenyl-3-yl}-3-hydroxy-propionic acid methyl ester 
• 143164-87-8 (2R,3S)-2-((2S,4R)-5-Benzyloxycarbonylamino-2-tert-butoxycarbonylamino-4-hydroxy-pentanoylamino)-3-{4,4'-bis-benzyloxy-3'-[(S)-2-benzyloxycarbonylamino-2-(2-trimethylsilanyl-ethoxycarbonyl)-ethyl]-biphenyl-3-yl}-3-hydroxy-propionic acid methyl ester 
• 143164-86-7 C₆₇H₈₀N₄O₁₅Si 
• 871206-25-6 (2S,3R)-2-((2S,4R)-2-Amino-5-benzyloxycarbonylamino-4-hydroxy-pentanoylamino)-3-[4,4'-bis-benzyloxy-3'-((S)-2-benzyloxycarbonylamino-2-pentafluorophenyloxycarbonyl-ethyl)-biphenyl-3-yl]-3-hydroxy-propionic acid methyl ester 
• 146388-30-9 (7R,8S,11S,14S)-5,17-Bis-benzyloxy-14-benzyloxycarbonylamino-11-((R)-3-benzyloxycarbonylamino-2-hydroxy-propyl)-7-hydroxy-10,13-dioxo-9,12-diaza-tricyclo[14.3.1.1^2,6]henicosa-1⁽¹⁹⁾,2⁽²¹⁾,3,5,16⁽²⁰⁾,17-hexaene-8-carboxylic acid methyl ester 
• 146388-31-0 (7R,8S,11S,14S)-5,17-Bis-benzyloxy-14-benzyloxycarbonylamino-11-((R)-3-benzyloxycarbonylamino-2-hydroxy-propyl)-7-hydroxy-10,13-dioxo-9,12-diaza-tricyclo[14.3.1.1^2,6]henicosa-1⁽¹⁹⁾,2⁽²¹⁾,3,5,16⁽²⁰⁾,17-hexaene-8-carboxylic acid 
• 146388-29-6 (2S,3R)-2-((2S,4R)-5-Benzyloxycarbonylamino-2-tert-butoxycarbonylamino-4-hydroxy-pentanoylamino)-3-[4,4'-bis-benzyloxy-3'-((S)-2-benzyloxycarbonylamino-2-pentafluorophenyloxycarbonyl-ethyl)-biphenyl-3-yl]-3-hydroxy-propionic acid methyl ester 
• 143164-84-5 3-<(S)-2-(benzyloxycarbonylamino)-2-(trimethylsilylethoxycarbonyl)ethyl>-3'-<(S)-2-(tert-butoxycarbonylamino)-2-(methoxycarbonyl)-(R)-1-hydroxyethyl>-4,4'-dibenzyloxybiphenyl 

Relevant academic research and scientific papers

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Synthesis of α- and β-carbon-linked serine analogues of the P(k) trisaccharide

The synthesis of glycopeptide ligands for a range of biomedically relevant carbohydrate-binding proteins is a topic of great importance to the glycobiology community. This task is impeded by the inherent instability of glycosyl linkages to serine/threonine, the normal sites of O-glycosylation in proteins. We have previously developed methodology for the preparation of C- glycosylated serines based on catalytic asymmetric hydrogenation of the corresponding enamide esters with the DuPHOS-Rh+ catalysts. Here we report further development of the methodology in the preparation of the C-glycosyl serine analogue of the pk trisaccharide (α-Gal(1→4)β-Gal(1→4)β-Glc-CH2- serine); we require these ligands for our continuing investigations of the binding subunit of the shiga-like toxin. Catalytic asymmetric hydrogenation was used to prepare both α- and β-C-glycosides in the R and S serine series. We report here on the tolerance of the DuPHOS catalysts toward acetate, benzoate, and benzyl hydroxyl protecting groups. Additionally, we have developed an amino acid protecting group strategy compatible with both asymmetric hydrogenation and solid-phase peptide synthesis. In the course of our studies, we have also developed a new methodology for regioselective reductive cleavage of benzylidene protecting groups.

Efficient stereoselective preparation of protected isodityrosines

A method for stereoselective preparation of isodityrosines with identical and orthogonal protecting groups is reported. The isodityrosines holding identical protecting groups were prepared from isovaniline in a three step procedure, in 50-64% yield (> 98% ee, 84-96% de). Isodityrosine holding four orthogonal groups was prepared in four steps from isovaniline in 20% total yield (> 98% ee, 87% de).